These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 20887676)
21. Research progression of CD133 as a marker of cancer stem cells. Zhang H; Li SY Chin J Cancer; 2010 Mar; 29(3):243-7. PubMed ID: 20193104 [TBL] [Abstract][Full Text] [Related]
22. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cheng JX; Liu BL; Zhang X Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008 [TBL] [Abstract][Full Text] [Related]
23. CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Kusumbe AP; Mali AM; Bapat SA Stem Cells; 2009 Mar; 27(3):498-508. PubMed ID: 19253934 [TBL] [Abstract][Full Text] [Related]
24. Cancer stem cell differentiation: TGFβ1 and versican may trigger molecules for the organization of tumor spheroids. Oktem G; Sercan O; Guven U; Uslu R; Uysal A; Goksel G; Ayla S; Bilir A Oncol Rep; 2014 Aug; 32(2):641-9. PubMed ID: 24927163 [TBL] [Abstract][Full Text] [Related]
25. Glioblastoma cancer stem cells--from concept to clinical application. Stopschinski BE; Beier CP; Beier D Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828 [TBL] [Abstract][Full Text] [Related]
26. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269 [TBL] [Abstract][Full Text] [Related]
27. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. Bidlingmaier S; Zhu X; Liu B J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813 [TBL] [Abstract][Full Text] [Related]
28. MicroRNA142-3p promotes tumor-initiating and radioresistant properties in malignant pediatric brain tumors. Lee YY; Yang YP; Huang MC; Wang ML; Yen SH; Huang PI; Chen YW; Chiou SH; Lan YT; Ma HI; Shih YH; Chen MT Cell Transplant; 2014; 23(4-5):669-90. PubMed ID: 24816458 [TBL] [Abstract][Full Text] [Related]
29. Glioma stem cell research for the development of immunotherapy. Ji J; Black KL; Yu JS Neurosurg Clin N Am; 2010 Jan; 21(1):159-66. PubMed ID: 19944974 [TBL] [Abstract][Full Text] [Related]
30. IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation. Chen Y; Zhang F; Tsai Y; Yang X; Yang L; Duan S; Wang X; Keng P; Lee SO Radiat Oncol; 2015 Nov; 10():227. PubMed ID: 26572130 [TBL] [Abstract][Full Text] [Related]
31. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949 [TBL] [Abstract][Full Text] [Related]
32. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. Kemper K; Versloot M; Cameron K; Colak S; de Sousa e Melo F; de Jong JH; Bleackley J; Vermeulen L; Versteeg R; Koster J; Medema JP Clin Cancer Res; 2012 Jun; 18(11):3132-41. PubMed ID: 22496204 [TBL] [Abstract][Full Text] [Related]
33. Neuroblastoma stem cells - mechanisms of chemoresistance and histone deacetylase inhibitors. Khalil MA; Hrabeta J; Cipro S; Stiborova M; Vicha A; Eckschlager T Neoplasma; 2012; 59(6):737-46. PubMed ID: 22862175 [TBL] [Abstract][Full Text] [Related]
34. Targeting CD133 antigen in cancer. Ferrandina G; Petrillo M; Bonanno G; Scambia G Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986 [TBL] [Abstract][Full Text] [Related]
35. Stem cell markers in gliomas. Dell'Albani P Neurochem Res; 2008 Dec; 33(12):2407-15. PubMed ID: 18493853 [TBL] [Abstract][Full Text] [Related]
36. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572 [TBL] [Abstract][Full Text] [Related]
37. CD133 as a target for colon cancer. Catalano V; Di Franco S; Iovino F; Dieli F; Stassi G; Todaro M Expert Opin Ther Targets; 2012 Mar; 16(3):259-67. PubMed ID: 22385077 [TBL] [Abstract][Full Text] [Related]
38. Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling. Jin X; Kim SH; Jeon HM; Beck S; Sohn YW; Yin J; Kim JK; Lim YC; Lee JH; Kim SH; Kang SH; Pian X; Song MS; Park JB; Chae YS; Chung YG; Lee SH; Choi YJ; Nam DH; Choi YK; Kim H Brain; 2012 Apr; 135(Pt 4):1055-69. PubMed ID: 22434214 [TBL] [Abstract][Full Text] [Related]
39. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells. Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273 [TBL] [Abstract][Full Text] [Related]
40. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Lottaz C; Beier D; Meyer K; Kumar P; Hermann A; Schwarz J; Junker M; Oefner PJ; Bogdahn U; Wischhusen J; Spang R; Storch A; Beier CP Cancer Res; 2010 Mar; 70(5):2030-40. PubMed ID: 20145155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]